Where are you?

To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.


Press Release, 8 January 2016

Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers

Cytos Biotechnology Ltd (“Cytos” or the “Company” – to be renamed Kuros Biosciences Ltd.), announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of the Board. Further, the newly constituted Board elected Didier Cowling as Chief Executive Officer, Dr. Alistair Irvine as Chief Business Officer, Dr. Jason Schense as Chief Technology Officer and confirmed Harry Welten as the Chief Financial Officer. All appointments are effective upon closing of the acquisition of Kuros Biosurgery Holding AG which is expected to take place within the next few weeks.


Schlieren (Zurich), Switzerland, January 8, 2016

“Yesterday, Cytos has received overwhelming support by our shareholders for the acquisition of Kuros Biosurgery Ltd. With the closing of the transaction most existing members of the Board will step down and new members of the Board of Directors have been elected. I would like to thank the outgoing Board members for their continued support and welcome the new members of the board and executive management”, commented Christian Itin, Chairman of Cytos. “We are pleased that Harry Welten will continue as Chief Financial Officer and are looking forward to forming Kuros Biosciences”.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward- looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

Cytos Biotechnology Ltd

Harry Welten, MBA Chief Financial Officer

Tel: +41 44 733 46 46